Phaseline

Companies › Haihe Biopharma

Haihe Biopharma: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CYH33
PIK3CA inhibitor
PIK3CAPhase 2Ovarian Cancer; PIK3CA-Related Overgrowth Spectrum (PROS)Dec 2029
HH2853–Phase 1Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL); FL LymphomaJul 2027
Glumetinib
MEK inhibitor
MAP2K1Phase 1C-Met Exon 14 Mutation–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04270591GlumetinibPhase 1C-Met Exon 14 MutationOtherOct 2023
NCT05043922CYH33Phase 2Ovarian CancerOncologyJul 2024
NCT06909877HH2853Phase 1Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)OncologyJul 2027
NCT04390737HH2853Phase 1FL LymphomaOncologyDec 2027
NCT06975618CYH33Phase 1PIK3CA-Related Overgrowth Spectrum (PROS)OtherDec 2029

Targets

PIK3CA (1) MAP2K1 (1)

Companies with the same targets

Eli Lilly Roche Novartis Recursion Pharmaceuticals TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Totus Medicines Risen (Suzhou) Pharma Tech iOnctura Restorbio Faeth Therapeutics

Companies built like this

Relay Therapeutics Ranok Therapeutics (Hangzhou) Shanghai Kechow Pharma Monte Rosa Therapeutics Beijing Tide Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.